Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group (Q41690799)

7 October 2017

title

Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group (English)

1 reference

7 October 2017

0 references

0 references

1 reference

Pneumocystis carinii

1 reference

8

D Havlir

1 reference

7 October 2017

M W Dunne

1

1 reference

7 October 2017

S Bozzette

2

1 reference

7 October 2017

J A McCutchan

3

1 reference

7 October 2017

M P Dubé

4

1 reference

7 October 2017

F R Sattler

5

1 reference

7 October 2017

D Forthal

6

1 reference

7 October 2017

C A Kemper

7

1 reference

7 October 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

7 October 2017

1 reference

7 October 2017

volume

354

1 reference

7 October 2017

issue

9182

1 reference

7 October 2017

page(s)

891-895

1 reference

Natural history of opportunistic disease in an HIV-infected urban clinical cohort

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Incidence Of Clinical Aids Conditions In A Cohort Of Homosexual Men With CD4+ Cell Counts <100/mm3

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Empiric outpatient management of HIV-related pneumonia: economical or unwise?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Activity of azithromycin against Mycobacterium avium infection in beige mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Azithromycin and terfenadine: lack of drug interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910328-8

7 January 2021

10.1016/S0140-6736(98)10328-8

Identifiers

DOI

1 reference

7 October 2017

1 reference